New insider activity at Guardant Health ( (GH) ) has taken place on August 22, 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CIO Kumud Kalia recently sold 2,000 shares of Guardant Health stock, amounting to a total transaction value of $123,500.
Recent Updates on GH stock
Guardant Health recently reported strong Q2 2025 earnings, with a 31% year-over-year revenue increase to $232 million, driven by robust performances in its oncology, biopharma, and screening segments. The company raised its full-year revenue guidance to $915-$925 million, reflecting confidence in its growth trajectory and market opportunities. Analysts have responded positively, with Scotiabank and TD Cowen raising their price targets due to the company’s impressive results, including the strong performance of the Guardant360 portfolio and Shield’s commercial success. Despite minor challenges such as ASP adjustments and regulatory uncertainties, Guardant Health’s strategic initiatives and improved gross margins underscore a positive outlook.
Spark’s Take on GH Stock
According to Spark, TipRanks’ AI Analyst, GH is a Neutral.
Guardant Health’s overall stock score is driven by strong technical indicators and a positive earnings call, which highlight significant revenue growth and improved margins. However, financial performance and valuation concerns due to ongoing losses and negative equity weigh down the score.
To see Spark’s full report on GH stock, click here.
More about Guardant Health
YTD Price Performance: 84.14%
Average Trading Volume: 2,447,458
Technical Sentiment Signal: Buy
Current Market Cap: $7.3B